Back to Sites Umlazi Clinical Research Site Site Number 30300 Address Umlazi CRS 1358 Mangosuthu Highway Umlazi, KwaZulu-Natal, 4066 South Africa IMPAACT Members at this Site Balungile Myeza CAB Member (not CRS Staff) Thumbi Ndung'u Co-Investigator Thandeka Nkosi Community Coordinator Scebi Nkosi Counselor Zukiswa Godlwana CRS Coordinator Dhayendre Moodley CRS Leader Zakir Gaffoor BS MMSc CTU Coordinator Quarraisha Abdool Karim CTU Principal Investigator Blanca Castillo DAIDS PO Eileen Pouliot DAIDS PO Linda Ngaleka Data Manager Moherndran Archary Investigator Hoosen Coovadia Investigator Kogieleum Naidoo Investigator Michelle Singh Investigator Natasha Samsunder Laboratory Director Natasha Samsunder Laboratory Manager/Supervisor Yurana Valjee Laboratory Technician Sylvano (Selven) Pillay Local Laboratory Devan Govender N/A Alicia Desmond Pharmacist Thusie Pather QA/QC Coordinator Natasha Pillay QA/QC Coordinator Vanessa Tombe Regulatory Coordinator Salim S. Abdool Karim Site Leader Studies at this Site IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development Pagination Previous page Prev Page 1 Current page 2
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV DAIDS Number 38747 Research Area Tuberculosis Study Status In Development
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Pending
IMPAACT 2040: Phase I/II Pharmacokinetics and safety of long-acting injectable Cabotegravir and Rilpivirine in people with virally suppressed HIV-1 during pregnancy and postpartum DAIDS Number 38953 Research Area Therapeutics Study Status Pending
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development